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Abstract
Objective. To evaluate the maternal, paternal, and fetal genotype contribution to preeclampsia.
Study design, materials, and methods. We combined the analysis of polymorphisms of the GSTP1, eNOS, and LPL genes –
affecting biotransformation enzymes and endothelial function – in a cohort of 167 preeclamptic and normal control trios
(mother, father, and child) comprising a total of 501 samples in the Greek population, never analyzed before by this
approach.
Results. For the frequency of the GSTP1 Ile
105/Val
105, the eNOS Glu298Asp and the LPL-93 polymorphisms, statistically
signiﬁcant differences were found between the two groups. However, the transmission rates of the parental alleles to
neonates studied by the transmission disequilibrium test, disclosed no increased rate of transmission to preeclampsia
children for the variant alleles of Val
105 GSTP1, 298Asp eNOS, and -93G LPL.
Conclusions. These novel data, suggest that interaction of all three types of genotypes (mother, father and neonate), reveals
no effects on the development of preeclampsia, but provide the impetus for further studies to decipher the individual
contribution of each genetic parameter of preeclampsia.
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Introduction
Preeclampsia represents the clinical expression of a com-
plex metabolic disorder during pregnancy, affecting 3–10%
of all pregnancies [1]. It is characterized by high maternal
and fetal morbidity and therefore, constitutes a high-risk
condition of pregnancy [2]. The main cause of this major
complication is still unknown. It is believed that genetic,
epigenetic, and environmental parameters are involved in
the pathogenesis of preeclampsia [3,4]. The most interest-
ing theory refers to the concept of an imbalanced lipid
peroxidation state, leading to the generation of reactive
oxygen species and toxic substrate accumulation, resulting
eventually in preeclampsia [2,5–9].
Glutathione S-transferase P1 (GSTP1), endothelial
nitric oxide synthase (eNOS), and lipoprotein lipase
(LPL) constitute three major detoxiﬁcation enzymes that
have been studied in pregnancy, as putative predisposing
factors to preeclampsia [10,11].
Glutathione S-transferase P1 transfers aliphatic, hetero-
cyclic radicals, epoxides, aren oxides substrates, and
xenobiotics to glutathione [12]. Glutathione S-transferase
P1-1 isoform (GSTP1-1) represents the main isoform in
placenta and decidua and exhibits lower levels in pre-
eclamptic pregnancies [13]. So far, two variant cDNAs
have been reported differing at one base pair (313 A-to-G
transition), resulting in an isoleucine to valine substitution
at position 105 (105 Ile!Val) and thus in a less functional
enzyme [14,15]. Therefore, Val 105 polymorphism results
in lower detoxiﬁcation in the trophoblast and thus
increases the oxidative status and susceptibility to pre-
eclampsia [16].
Nitric oxide (NO) and its signaling cascade are important
for the placental function and particularly for the regulation
of blood ﬂow and vasomotor tone [17]. It is synthesized by
the endothelial nitric oxide synthase (eNOS). The eNOS
Glu298Asp gene polymorphism has been reported to be
associated with severe preeclampsia [18,19], but not in all
populations studied [20–22]. Polymorphisms of the eNOS
gene detected in 9–13% of the general population may
affect its functional capacity. The common missense
variant Glu298Asp polymorphism seems to enhance
enzyme proteolytic capacity and results to low NO
bioactivity [23] and reduced endothelium-dependent
vasodilation.
LPL hydrolyzes and releases the free fatty acids from the
very low-density lipoproteins (VLDL) and chylomicrons
[24]. LPL deﬁciency results in aberrant fatty acid
metabolism. Many mutations have been described so far
and their frequency has been estimated to be 1:500
individuals [24–26]. Furthermore, mutations in the coding
region of the LPL gene have been associated with
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substitution of T to G at the proximal promoter region, i.e.
(-93 position), resulting in a functional variant with
aberrant transcriptional activity, associated with coronary
artery disease, dyslipidemia, atherosclerosis, and pree-
clampsia [28,29]. However, this variant has not been
associated with an increased risk for preeclampsia in white
North American patients [30].
A large Swedish cohort population study showed that
maternal genes may contribute to preeclampsia by 35%,
fetal genes by 20%, while 13% was attributable to the
couple effect, 32% to undetermined factors and less than
1% to shared sibling environment [31]. The fetus con-
tribution is affected by paternal genes; on the contrary,
maternally transmitted mitochondrial genes do not con-
tribute to the risk [32]. Extensive genotyping studies
[33,34] excluded several genetic variants as putative risk
factors, while they documented that a paternal, but not
maternal history of essential hypertension is associated with
increased risk of nonpregnant hypertension in the children.
Thus, placenta and the fetus reﬂect in part, the paternal
component of the pregnancy and their unique genotypes
may contribute to the development of preeclampsia, under
a speciﬁc maternal genotype. However, this rather new
approach of evaluation of the role of paternal–fetal
genotype on the susceptibility for preeclampsia has led to
inconsistent and conﬂicting results in the few studies
conducted so far [16,33–37]. The reasons for this failure
might reﬂect analysis of individual single-gene polymorph-
isms, or evaluation of genes not linked pathophysiologically
to the mechanisms of preeclampsia, or the effects of
different genetic backgrounds of the ethnic groups
analyzed, or ﬁnally, small size of samples. Therefore, it is
necessary to evaluate and delineate more systematically the
contribution of the maternal and fetal genotypes, by using a
combined analysis of a series of candidate genes directly
involved in the pathophysiology of preeclampsia.
To this end, and based on previous data, we designed a
case–control study to evaluate the contribution of maternal
and paternal–fetal components for the risk of preeclampsia,
by analyzing the effects on preeclampsia risk of the three
relatively common polymorphisms of the GSTP1, eNOS,
and LPL genes in a cohort of preeclamptic and normal
control trios (mother, father, and child) belonging to a
different ethnic population (i.e. Greek) never analyzed
previously by this approach. We hypothesized that these
gene polymorphisms might constitute a basis for the
triggering events leading to preeclampsia, by affecting the
activity of biotransformation enzymes (GSTP1 and eNOS)
in detoxifying processes and/or the endothelial function
(LPL).
Materials and methods
Patients and study subjects for DNA polymorphisms
The prospective case–control study enrolled 167 unrelated
pregnant women participating as trios (mother, father, and
neonate), 51 (30.95%) with preeclampsia, and 116
(69.05%) healthy pregnant women, as controls. Thus,
the total population studied comprised of 501 samples.
Subjects were recruited from the Obstetric Clinic of the
First Department of Obstetrics and Gynecology, at the
University of Athens School Medicine. All pregnant
women were on singleton pregnancy, while the fetuses of
polypara preeclamptic women were fathered by the same
father. Participants’ mean age was 27.6+4.7 years. None
of the women were on medication, except of a subgroup of
cases, requiring regimen for maintaining normotensive
status. Each participating individual provided informed
consent. Institutional Review Board approval for the study
was obtained by the University Hospital Ethics Committee.
Basic demographic and clinical parameters, such as
gestational age, height, body weight and body mass index
(BMI) before pregnancy, systolic and diastolic blood
pressure, liver enzymes, urine protein, serum creatinine,
platelet count, right upper quadratic pain, edema, and
visual disorders, were recorded for all subjects. All pregnant
women underwent serum and urine specimen analysis
before labor.
Preeclampsia was deﬁned as the occurrence, after the
20th gestational week, of systolic blood pressure greater
than 140 mm Hg and of diastolic blood pressure greater
than 90 mm Hg on two or more recording times with at
least 4 h apart, combined with proteinuria with urine
protein excretion greater than  0.3 g/day or  2þ on one
voided dipstick testing of midstream urine. Women with
hypertension prior to pregnancy, diabetes mellitus, renal or
cardiac disease, were excluded from the study.
On the basis of the aforementioned criteria, the deﬁnitive
diagnosis for preeclampsia was made at or after the 26th
gestational week, while following delivery, 5 ml of venous
blood was drawn from each one of the triplet (mother,
father, and neonate) and collected in EDTA-containing
tubes. The samples were stored at 7808C until analyzed.
Every triplet was studied for eNOS, GSTP1, and LPL
polymorphisms.
DNA extraction and analysis of gene polymorphisms
Genomic DNA was extracted from whole blood using the
NucleoSpin Blood Kit (Macherey-Nagel, Bioanalysis,
GmbH & Co. KG, Du ¨ren, Germany), according to the
instructions of the manufacturer. The procedure typically
resulted in the isolation of 50–200 ng of genomic DNA.
Polymorphisms for glutathione S-transferase P1
(GSTP1), endothelial nitric oxide synthase (eNOS), and
lipoprotein lipase (LPL) genes were detected by a
combination of polymerase chain reaction (PCR) and
restriction fragment length polymorphism (RFLP) assays,
using appropriate restriction enzymes as described pre-
viously [16,23,29]. The primers used (forward and reverse)
for the polymorphic loci are shown in Table I. All chemicals
for PCR were purchased from Minotech (FoRTH,
Table I. Primer pair sequences used in PCR for the detection of
the three gene polymorphisms.
Gene Marker Location Primer (50 to 30)
GSTP1 Exon 5 Forward 50-ACCCCAGGGCTC
TATGGGAA-30
Reverse 50-TGAGGGCACAAGA
AGCCCCT-30
eNOS Exon 7 Forward 50-AGGAAACGGTCG
CTTCGACGTGCTG-30
Reverse 50-CCCCTCCATCCCA
CCCAGTCAAC-30
LPL -93 position of
promoter region
Forward 50-GGCAGGGTTGAT
CCTCATTACTGTT-30
Reverse 50-GACACTGTTTTCA
CGCCAAGGCTGC-30
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ampliﬁed products were resolved on a 4% agarose gel
electrophoresis, as shown in Figure 1.
The PCR reaction was carried out in a total volume of
30 ml in a PTC-200 Peltier Thermal Cycler (MJ Research,
Waltham, MA). The PCR reaction mixture contained 3 ml
106 reaction buffer, 1 ml dNTP mix (10 mM of each
dNTP), 1 ml forward primer (25 pmol), 1 ml reverse
primer (25 pmol), 1.8 ml MgCl2 (25 mM), 1 ml Taq
DNA polymerase (5 u/ml), and 5 ng/ml DNA template.
Ampliﬁcation was carried out with 5 min initial denatura-
tion at 958C, followed by 35 cycles of denaturation at 958C
for 30 s, primer annealing at the appropriate temperature
for each primer for 30 s, and extension at 728C for 1 min.
For GSTP1, the PCR yielded a 176-bp product, and
following digestion with the restriction enzyme BsmA I, an
isoschizomer of Alw26 I (New England BioLabs, Beverly,
MA), yielded a 93- and a 83-bp product for the G/G
genotype, a 176-, a 93-, and a 83-bp product for the A/G
genotype, while the enzyme did not cut the normal A/A
genotype sequence (Figure 1).
For eNOS, the PCR yielded a 152-bp product, which,
after digestion with the restriction enzyme Ban II (New
England BioLabs), yielded a 98- and a 54-bp fragment for
the normal G/G genotype, a 152-, a 98- and a 54-bp
fragment for the T/G genotype, while the PCR product
with the T/T genotype was not digested (Figure 1).
For the LPL-93 polymorphism, the PCR yielded a 149-
bp product, which following digestion with the restriction
enzyme Ban II, yielded a 93- and a 56-bp fragment for the
G/G genotype, a 149-, a 93-, and a 56-bp fragment for the
T/G genotype, while the PCR product with the normal
T/T genotype was not digested (Figure 1).
Statistical analysis
For the statistical analysis, the nonparametric tests of two-
sample Wilcoxon matched-pairs rank-sum test and the w
2
Fisher’s exact test were applied accordingly. For the
statistical analysis of the polymorphisms, the w
2 Fisher’s
exact test was used. The number of parental–fetal allele
transmissions compared to the number of transmissions
expected by chance was studied using the transmission
disequilibrium test (TDT) [38]. The level of statistical
signiﬁcance was deﬁned as P50.05.
Results
Clinical and biochemical features of the two groups of pregnant
women
The initial total population studied comprised of 504
individuals (i.e. 168 mothers, their corresponding 168
husbands, and 168 children) from each trio. Because of the
lack of information for one child, 167 trios were ﬁnally
evaluated for genotyping.
The main demographic and clinical features of the two
groups of pregnant women (i.e. preeclamptic and normal
controls) are shown in Table II. All the clinical and
biochemical parameters between the two groups with the
exception of platelet count were statistically signiﬁcant.
Speciﬁcally, the prepregnancy BMI, systolic and diastolic
blood pressure, serum GOT, GPT, and creatinine levels
were higher in the preeclamptic group, and all differences
were statistically signiﬁcant (P50.001), as shown in
TableII.Furthermore,alltheadditionalquantitativeclinical
parameters studied, such as right-upper quadrant pain
(P¼0.009), edema (P50.001), headache (P50.001),
visual disorders (P50.001), and urine protein
(P50.001), were found to be statistically signiﬁcant
between the two groups, using the w
2 Fisher’s exact test.
Genotypic frequencies of the three polymorphic alleles in the two
groups
We next studied the distribution of the frequencies of
GSTP1, eNOS, and LPL genotypes in the subgroups of
Figure 1. Evaluation of the polymorphisms for the GSTP1, eNOS, and LPL genes, using a combination of PCR analysis, followed by
restriction enzyme digestion and resolution of the digested PCR products by electrophoresis in 4% agarose gels. Representative trios (father,
F; mother, M; and child, C) with their respective genotypes for each gene are shown. The size of the expected digested products, in base
pairs (bp), is shown on the right of each panel. The ﬁrst lane of each panel contains bands of the 50 bp DNA ladder, ranging from 50 to
1350 bp, used as molecular weight standards.
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normal control groups. The comparisons were performed
using the Fisher’s exact test. The distribution of the
polymorphic variants of the three genes in the preeclampsia
trios and the normal control group is shown in Table III.
For the GSTP1 polymorphism, the frequency of the
variant Val
105 allele, although previously reported to be
associated with preeclampsia [16] was found to be higher
in mothers (25.8%) and fathers (25.0%) of normal
pregnancies compared to the preeclamptic group, while a
statistically signiﬁcant difference was detected between the
frequency of the individual subgroups compared to that of
the normal controls (P¼0.013 and P¼0.001, respec-
tively). It is noteworthy, that no homozygote for the Val
105
allele was found among the fathers of the preeclampsia
trios (Table III).
For the eNOS Glu298Asp polymorphism, a similar
pattern of frequency distribution was observed (Table III).
The frequency of the 298Asp allele was higher in mothers
(29.7%), fathers (34.4%) and children (32.3%) of the
normal control group compared to the preeclamptic group
and a statistically signiﬁcant difference was detected
between the individual subgroups (P¼0.001, P¼0.002,
and P¼0.025, respectively). No homozygote individual for
the 298Asp/298Asp genotype was found in the group of
preeclamptic mothers and fathers.
For the -93LPL polymorphism of the promoter region,
the frequency of the variant -93G allele was higher in
mothers (4.9%), fathers (1.9%), and children (2.9%) of
preeclamptic pregnancies compared to the normal control
subgroups. However, when the frequencies of the indivi-
dual subgroups of preeclampsia were compared to those of
the normal controls, a statistically signiﬁcant difference was
documented only for the mothers (P¼0.047), while no
statistically signiﬁcant difference was documented between
the subgroups of fathers (P¼0.317) or of the children
(P¼0.153).
Transmission pattern of the preeclamptic parental allele to
neonates
We next investigated the mode of transmission of the
associated marker allele from a heterozygous parent to an
affected, in this case, neonate of a preeclamptic pregnancy.
To this end, we have utilized the transmission disequili-
brium test or TDT [38] developed as a test for linkage
between a complex disease, such as preeclampsia and a
genetic marker, such as the polymorphic alleles of the
GSTP1, eNOS, and LPL genes. The TDT actually
evaluates the observed number of parent–child transmis-
sions of alleles, compared to the number of transmissions
anticipated by chance. The TDT test was applied in cases
where at least one parent was heterozygote for the
polymorphism, since only heterozygotes are informative
for the test.
For the GSTP1 polymorphism, a total of 56 transmis-
sions of the variant Val
105 allele, and 118 transmissions of
Table III. Distribution of the GSTP1, eNOS, and LPL
polymorphisms in mother, father, and neonate trios of the two
groups.
Genotype
n (%)
P-
value* Preeclampsia Normal controls
GSTP1 gene
Mother Ile
105/Ile
105 34 (66.67) 68 (58.62)
Ile
105/Val
105 15 (29.41) 36 (31.03) 0.013
Val
105/Val
105 2 (3.92) 12 (10.34)
Father Ile
105/Ile
105 28 (54.90) 68 (58.62)
Ile
105/Val
105 23 (45.10) 38 (32.76) 0.001
Val
105/Val
105 0 (0.00) 10 (8.62)
Child Ile
105/Ile
105 38 (74.51) 69 (59.48)
Ile
105/ Val
105 11 (21.57) 38 (32.76) 0.007
Val
105/Val
105 2 (3.92) 9 (7.76)
eNOS gene
Mother 298Glu/298Glu 22 (43.14) 57 (49.14)
298Glu/298Asp 29 (56.86) 49 (42.24) 0.001
298Asp/298Asp 0 (0.00) 10 (8.62)
Father 298Glu/298Glu 27 (52.94) 44 (37.93)
298Glu/298Asp 24 (47.06) 64 (57.17) 0.002
298Asp/298Asp 0 (0.00) 8 (6.90)
Child 298Glu/298Glu 24 (47.06) 50 (43.10)
298Glu/298Asp 25 (49.02) 57 (49.14) 0.025
298Asp/298Asp 2 (3.92) 9 (7.76)
LPL gene
Mother 793T/793T 46 (90.20) 113 (97.41)
793T/793G 5 (9.80) 3 (2.59) 0.047
Father 793T/793T 49 (96.08) 113 (97.41)
793T/793G 2 (3.92) 3 (2.59) 0.317
Child 793T/793T 49 (96.08) 111 (95.69)
793T/793G 1 (1.96) 4 (3.45) 0.153
793G/793G 1 (1.96) 1 (0.86)
*P-values were generated using w
2 Pearson’s test. Where neces-
sary, the corresponding Fisher’s exact test was also used.
Table II. Selected demographic and clinical features of the two groups of pregnant women.
Preeclampsia (n¼51) Normal controls (n¼116) P-value*
Age (years)** 26 (18–36) 27 (21–37) 0.023
Pre-pregnancy BMI (kg/m
2)** 25.2 (18.6–34.7) 21.5 (18.4–31.1) 50.001
Systolic blood pressure (mm Hg)** 159.0 (100–230) 110 (100–120) 50.001
Diastolic blood pressure (mm Hg)** 100 (70–150) 75 (65–80) 50.001
Serum GOT
{ (U/l)** 23 (7–129) 13 (9–34) 50.001
Serum GPT
{ (U/l)** 20.0 (7–466) 12 (6–52) 50.001
Creatinine (mg/dl)** 0.70 (0.36–1.30) 0.60 (0.40–0.70) 50.001
*The comparison between the two groups, due to the non-normal distribution of the variables, was performed using the nonparametric
criteria of the two-sample Wilcoxon matched-pairs rank-sums test, which is equivalent to the Mann–Whitney test.
**The appropriate values of median and range were used, since the distribution of these continuous variables is not normal.
{GOT, glutamic oxaloacetic transaminase.
{GPT, glutamic pyruvic transaminase.
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105 allele, from 87 parents were observed.
The application of the TDT test was found to be not
statistically signiﬁcant (P¼0.074), indicating that there is
no difference in the rate of transmission of the common
lle
105 allele versus the variant allele Val
105 to preeclampsia
children.
For the eNOS polymorphism, 87 transmissions of the
variant 298Asp allele and 151 transmissions of the
common 298Glu allele were observed in a total of 119
parents. The TDT test was not statistically signiﬁcant
(P¼0.677). Therefore, there is no increased transmission
of the variant 298Asp allele to the preeclampsia children.
For the -93LPL polymorphism, six transmissions of
the variant -93G allele and 16 transmissions of the common
-93T allele were observed in 11 parents. The TDT test was
not found to be statistically signiﬁcant (P¼1.00). Therefore,
the data suggest no increased transmission frequency of the
variant allele to preeclampsia children.
Discussion
Maternal susceptibility to preeclampsia is a multifactorial
and complex process, involving the contribution of a series
of essential gene variants [3,4,39], affecting hemodynamic
and vascular parameters, oxidative stress pathways causing
endothelial damage and induction of metabolic and
coagulation aberrations.
Furthermore, the central role of placenta and the
epigenetics of the placentally expressed genes are currently
recognized as the cardinal features of the pathophysiology
of preeclampsia [3,4]. Speciﬁcally, expression analysis of
preeclamptic placental genes has revealed a group of
numerous target genes putatively involved in abnormal
placentation [40] and another set of 13 genes signiﬁcantly
upregulated, with functions involving tumor suppression,
growth regulation, and inhibition of trophoblast invasion
[41]. These gene sets can be further evaluated for their
triggering role in preeclampsia.
Although such studies are expected to delineate the
multivariable parameters of preeclampsia mechanisms,
additional complementary approaches are also needed to
address the issues of the individual contribution of the
parental and fetal genotypes to the risk for preeclampsia.
Familial studies have convincingly supported the hypoth-
esis that transmission of the father’s genes to the fetus
(actually to placenta) can indeed increase the risk for
preeclampsia [32,42]. More recent studies using linked
birth data among family members in Norway [36] and in
Malay women in Singapore [37], have further provided
evidence that both maternal and fetal genes either from the
mother or the father, can trigger the mechanisms of
preeclampsia. Thus, maternal susceptibility seems to be
mediated by a combination of maternal susceptibility genes
and by an independent transmission to the fetus of genetic
risk factors. It is of interest, that in the Norwegian study
[36] the data strongly suggested that there was a differential
contribution between the maternal and paternal compo-
nents; mothers seem to carry both susceptibility genes and
also transmit independent genetic risk factors to the fetus,
while fathers transmit only fetal risk factors. The validity of
these ﬁndings, have been followed up by a series of large-
scale multicenter candidate gene studies [33,34] aiming to
identify fetal and maternal susceptibility for preeclampsia,
involving extensive genotyping of seven candidate genes,
previously considered to confer susceptibility to pree-
clampsia. However, none of the seven selective genetic
maternal and fetal variants were found to confer a high risk
for preeclampsia. This failure, probably reﬂects, among
other reasons, the lack of inclusion of additional
preeclampsia-speciﬁc genes [10,43] which could eventually
provide a better understanding of the pathogenetic
mechanisms of preeclampsia.
It is therefore evident that a comprehensive approach is
needed to decipher the mechanisms of susceptibility to
preeclampsia, by encompassing all the genetic components
involved in the formation of placenta (i.e. maternal,
paternal, and fetal genotypes). This new approach has
been used so far in a single study to address the effect of the
paternal contribution, by studying the GSTP1 gene
polymorphism in a cohort of 113 preeclampsia trios in
the Dutch population [16]. The paternal and fetal
polymorphism of the GSTP1 gene was found to be
associated with a high risk for preeclampsia [16]. This
polymorphism had been associated earlier by the same
group [14] in the maternal genome of preeclamptic
women, while no association had been found in either
preeclampsia, eclampsia or HELLP syndrome in the
maternal genome of a different ethnic group for a
polymorphism of two closely related cytosolic soluble
glutathione S-transferase genes of the mu (M) and theta
(T) families [44]. It is of interest that homozygosity for the
Val
105 polymorphism was associated with severe pree-
clampsia because of the production of a GSTP1 enzyme
with reduced detoxifying capacity [15,16,45,46]. In con-
trast, another study [47] has reported a high frequency of
the Val
105/Val
105 genotype in maternal and fetal samples in
a South African population, but with no proportional
increase in preeclampsia. It has also been speculated that
the GSTP1 variant contributes to preeclampsia phenotype
despite the fact that the frequency of the Ile
105/Val
105and
Val
105/Val
105 genotypes was not signiﬁcantly different
between the preeclampsia and the control group [48].
On the basis of these limited and conﬂicting studies, we
designed this study to evaluate more systematically the
contribution of maternal, paternal, and fetal components
for the risk of preeclampsia, by selecting three gene
polymorphisms, affecting the activity of biotransformation
enzymes, such as GSTP1 and eNOS, and the endothelial
function, such as LPL, in an ethnic population (i.e. Greek)
never analyzed previously by this comprehensive approach.
We hypothesized that detoxiﬁcation and endothelial
function-linked paternal gene variants inherited by the
fetus are expressed in the fetal–placental unit, and under a
speciﬁc background of maternal genotype, they might
trigger a hyperoxidative status, which is eventually mani-
fested as preeclampsia.
The genotypic distribution and the frequencies of the
three polymorphic alleles between the preeclampsia and
the normal control trios revealed several informative
features between the two groups.
For the GSTP1 polymorphism, the frequency of the
variant Val
105 allele interestingly was found to be higher in
mothers and fathers of normal pregnancies compared to
the preeclampsia group, a ﬁnding nonconsistent with
previous data [16]. Furthermore, this difference was
statistically signiﬁcant, and the TDT test applied to the
heterozygote parents for the variant allele Val
105, disclosed
no difference in the rate of transmission versus the
common Ile
105 allele to preeclamptic children. These data
are in contrast to those performed on the Dutch population
[16]. These discrepancies between the two studies
apparently reﬂect different allele frequencies between the
two ethnic populations and discrete genotype backgrounds
regarding the individual putative alleles contributing to
preeclampsia. Actually, candidate gene studies underscore
632 K. I. Pappa et al.the fact that single-gene effects may be variable across
populations [4,49,50].
For the eNOS polymorphism, the frequency of the
variant 298Asp allele was found to be statistically
signiﬁcant between the two groups of trios, exhibiting
higher frequency in the control group. Furthermore, the
TDT test applied to 87 transmission patterns was not
statistically signiﬁcant. These data represent the ﬁrst
attempt to evaluate the contribution of all three types of
eNOS genotypes in a preeclamptic group. Previous
studies, using analysis of simple maternal genotypes, have
associated the 298Asp allele with severe preeclampsia in
some [18] but not in all populations studied [20]. It should
be noted also that this variant allele is represented in
9–13% of the general population and seems to affect the
proteolytic activity and bioactivity of NO [23], resulting in
reduced endothelium-dependent vasodilation, a state that
can lead to preeclampsia.
In addition, a different polymorphism of the eNOS gene
within intron 4 (designated as allele A) has been shown to
be associated with preeclampsia in a deﬁned ethnic group
[51]. The odds ratio of developing preeclampsia when at
least one A allele was present was 6.5, suggesting that this
polymorphism might have predictive value for preeclamp-
sia. Finally, a recent extensive meta-analysis of the eNOS
Glu298Asp polymorphism involving 1055 patients and
1788 controls did not reveal any clear association with
preeclampsia [52]. Therefore, the data from our studies and
those of other investigators imply that the eNOS poly-
morphism per se is not sufﬁcient to clearly confer predis-
position to preeclampsia. Further studies are thus needed to
clarify additional regulatory parameters of the eNOS-NO
activity in normal placenta, such as novel peptides, i.e.
adiponectin, apelin, and ghrelin 91 and 92 that utilize the
NO pathway to modulate vascular tone [17].
Regarding the frequency distribution and the effect of
paternal–fetal transmission of the LPL gene polymorphic
genotypes, consistent frequency differences of the two
alleles between the subgroups of the two categories were
documented, with the frequency of the variant -93G allele
being higher in mothers, fathers, and children of pre-
eclamptic pregnancies. These data are consistent with
previous ﬁndings in Caucasian women concerning the
frequency and association of the variant -93G allele with
preeclampsia [29]; however, this variant did not exhibit an
increased risk in another subsequent study in white North
American women [30]. Furthermore, the transmission
analysis using the TDT test used for the ﬁrst time in our
study disclosed that there was no increased transmission
frequency of the variant allele to preeclamptic neonates.
Since dyslipidemia, a state that predisposes to pre-
eclampsia, reﬂects a multifactorial and multigene disorder,
it is not surprising that the limited data so far on -93LPL
polymorphism, based solely on the analysis of maternal
genotypes, have led to inconsistent results, suggesting
either association to preeclampsia [28,29,53] or no
association, when tested in a series of white North
American patients [30].
In conclusion, we have used a comprehensive approach
for the delineation of the individual maternal, paternal, and
fetal genotypes for the risk of preeclampsia, utilizing for the
ﬁrst time the combined analysis of three key gene
polymorphisms, affecting the activity of biotransformation
enzymes (GSTP1 and eNOS) in detoxifying processes and/
or the endothelial function of placenta (LPL) in a different
ethnic population never analyzed before by this approach.
These novel data, based on the transmission test for
linkage disequilibrium (TDT), suggest that analysis of the
interaction of all three types of genotypes (mother, father,
and neonate) from the preeclampsia and control groups
reveals variable effects. The GSTP1 polymorphism with its
variant Val
105 allele is not sufﬁcient to clearly confer an
increased risk for preeclampsia, neither the eNOS poly-
morphism with the variant 298Asp allele, nor the LPL gene
polymorphism with the -93G variant allele.
Our studies using a different approach, document the
molecular and racial heterogeneity of preeclampsia, and
provide the impetus for further studies involving (i) the
analysis of additional genomic regions revealed by
genome scan meta-analysis [4] and (ii) employing large-
scale genome-wide association studies [3], to decipher the
individual contribution of each genetic and epigenetic
parameter [11] of preeclampsia.
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